[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415844":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":91,"collaborators":93,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":10,"enrollmentInfo":111,"targetDuration":114,"studyType":115,"phases":10,"briefSummary":116,"conditions":117,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Localized and locally advanced prostate cancer",null,"Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.",[13],"Other: standard of care",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"standard of care","No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation.\n\nClinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically.\n\nAll treatment decisions will be made at the discretion of the investigator or treating physician.",[9],[20],{"name":21,"affiliation":22,"role":23},"Wouter Everaerts, MD, PhD","UZ Leuven \u002F KU Leuven","PRINCIPAL_INVESTIGATOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+3216346687","wouter.everaerts@uzleuven.be",[30,48,64,78],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"AZ Sint-Blasius","RECRUITING","Dendermonde","Oost-Vlaanderen","9200","Belgium","BE",{"type":39,"coordinates":40},"Point",[41,42],4.10106,51.02869,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":47,"phoneExt":10,"email":10},"Dieter Ost, MD, PhD","052 25 25 05",{"facility":49,"status":32,"city":50,"state":51,"zip":52,"country":36,"countryCode":37,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"University Hospitals Leuven","Leuven","Vlaams-Brabant","3000",{"type":39,"coordinates":54},[55,56],4.70093,50.87959,{"lat":56,"lon":55},[59,61],{"name":21,"role":26,"phone":60,"phoneExt":10,"email":28},"016346687",{"name":62,"role":63,"phone":10,"phoneExt":10,"email":10},"Andries Clinckaert, MD","SUB_INVESTIGATOR",{"facility":65,"status":32,"city":66,"state":67,"zip":68,"country":36,"countryCode":37,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"AZ Sint-Jan Brugge","Bruges","West-Vlaanderen","8000",{"type":39,"coordinates":70},[71,72],3.22424,51.20892,{"lat":72,"lon":71},[75],{"name":76,"role":26,"phone":77,"phoneExt":10,"email":10},"Pieter Uvin, MD, PhD","050 45 25 30",{"facility":79,"status":32,"city":80,"state":67,"zip":81,"country":36,"countryCode":37,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"AZ Groeninge Kortrijk","Kortrijk","8500",{"type":39,"coordinates":83},[84,85],3.26487,50.82803,{"lat":85,"lon":84},[88],{"name":89,"role":26,"phone":90,"phoneExt":10,"email":10},"Siska Van Bruwaene, MD, PhD","056 63 38 00",{"type":92,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[94,96,98],{"name":95,"class":6},"AZ Sint-Jan AV",{"name":97,"class":6},"General Hospital Groeninge",{"name":99,"class":100},"AZ Sint-Blasius Dendermonde","UNKNOWN","100415844","prospective-prostate-cancer-and-patient-reported-outcomes-registry-100415844",false,"NCT04694924","Prospective Prostate Cancer and Patient-reported Outcomes Registry","Promoting Quality of Care: a Prospective Cohort Study of Localized and Locally Advanced Prostate Cancer Patients","Prosquare","Inclusion Criteria:\n\n* Pathology confirmed diagnosis of localized or locally advanced prostate cancer\n* Being able to speak, read and understand Dutch, French, or English\n* Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he understands the purpose of, and is willing to participate in the study.\n\nExclusion Criteria:\n\n* Patients with prior treatment for prostate malignancies will be excluded.\n* Dementia, mental alteration, or psychiatric pathology that can compromise informed consent from the patient and\u002F or adherence to the protocol and the monitoring of the trial\n* Patients who cannot submit themselves to following the protocol for psychological reasons, social, family, or geographical.\n* Persons deprived of liberty or under guardianship","MALE","18 Years",{"count":112,"type":113},5000,"ESTIMATED","10 Years","OBSERVATIONAL","This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.",[118,119,120,121],"Prostate Cancer","Adenocarcinoma of the Prostate","Locally Advanced Prostate Carcinoma","Locally Advanced Prostate Adenocarcinoma","2024-05-21",{"date":124,"type":125},"2024-05-22","ACTUAL",{"date":127,"type":125},"2020-10-01",{"date":129,"type":113},"2030-10",{"name":5,"class":6},4]